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Improving the acceptability of high-dose radiotherapy by reducing the
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Smaqy Radiotherapy, although clearly benefical in patients with high-grade glioma, is largely pallianve,
and a protracted course of treatment may not be the most appropriate approach in the context of imited
surval. We therefore assessed the feasibility, toxicity and survival results of a short accelerated radiotherapy
regimen given twice daily over a period of 3 weeks. A total of 116 patients with high-grade glioma were
treated with radiotherapy in a prospective study usin an accekerated fractionation regimen. The total dose of
55 Gy was given in 32-36 fractions of 1.72-1.53 Gy, twice daily 5 days a week, with a minium 6h interval
betwe frions. Toxicity was assesed usg Kanofsky perfomance status scale and in the later part of the
study with the Barthel index. Survival data were cpared with a control group treated with 60 Gy in 30 daily
fractions in a previous MRC study, matched for known prognosti factors. The median survival of 116
patients treated with asmlerated radiotherapy was 10 months. Survival comparison ofaccelerated patients with
matched controls treated with conventional fractionation demonstrated a hazard ratio of 1.13 (95% confidence
interval 0.85-1.51; P = 0.39). Early treatment toxicity was acceptabie, with only seven patients developing
tansient decase in performance status. The accerated radiotherapy regimen was logistically feasible and
acceptable to patients, carers and staff. Treatment time was reduced without apparent increase in early toxicity
and there was no loss of survival benefit The effectiveness and convenience of a short accelerated rgimen
makes this a suitable alternative to a 6 week course of radiotherapy in patients with high-grade ghoma.
However, a full randomised trial comparing conventional and acceklrated radiotherapy may be required as
proof of equivalence.
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Radiotherapy continues to be the mainstay of treatment of
patients with high-grade glioma. It prolongs survival and
usually maintains quality of life by retaining or inproving
neurological function for the duration of tumour control.
Conventional radiotherapy schedules test in randomised
studies involve a protracted course of irradiation usually to a
dose of 60 Gy in 6 weeks. The treatment is given in doses
s< 2 Gy per fraction to avoid late normal tissue damage to
the central nervous system (CNS), which is highly fractiona-
tion dependent.
While in terms of survival a radiotherapy treatment
schedule of60 Gy in 6 weeks is considered optimal (Chang et
al., 1983; Bleehen et al., 1991), the overaD survival ofpatients
with high-grade glioma remains poor, and the purpose of
such a protracted high-dose irradiation schedule is largely
palliative. In patients destined to survive less than 6 months,
who constitute 30% of high-grade glioma patients in an
average cohort, 6 weeks' treatment represents 25% or more
of remaining life, and this may not be acceptable to patients,
relatives and physicans.
Treatment time can be shortened without reducing the
biologically effective tumour dose either by reducing the
number of fractions and increasing the dose per fraction
(hypofractionation) or by giving the same number of frac-
tions treating more than once a day (accelerated fractiona-
tion). The former approach may lead to an increased risk of
late normal tissue damage to the brain unless the total radia-
tion dose is reduced. The latter regimen in which multiple
fractions are given each day at conventional dose per frac-
tion, is also not without disadvantages. Repair of radiation
damar in normal tissue may be incomplete in the short time
interval between fractions (Ang et al., 1992), and this may
increase the risk of normal tissue toxicity. The logistics of
twie-daily treatment also imposes strain on the normal func-
tioning of the radiotherapy department and requires assigned
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machine treatment time at the two ends of the day. In
addition, patients have to live close to the treatment facility
or may require admission or day care to be able to attend in
the early morning and late afternoon. Nevertheless, some
would consider it a major advantage to complete treatment
in 3 rather than 6 weeks.
We set out to examine the efficacy and toxicity of
accelerated twice-daily radiotherapy in a prospective single-
arm study. The results were compared with a matched cohort
of patients treated with conventional daily irradiation
selected from the MRC BR2 study (Bleehen et al., 1991) on
the basis of known prognostic factors (Table I).
r.P teh and mwthods
Between August 1988 and June 1993, 116 patients with high-
grade glioma (Table I) were treated with accelerated
radiotherapy at The Royal Marsden Hospital. Seventy-four
were men and 47 women, aged 19-77 years (median 56
years). Thirty-two patients had grade HII and 44 grade IV
astrocytoma (Kernohan and Sayre, 1952). Thirty-nine
patients had high-grade tumours not otherwise specified. The
presurgical Karnofsky performance status ranged from 10 to
100 (median 90) and preradiotherapy status was 40-100
(median 90). The follow-up ofsurviving patients ranged from
2 months to 37 months (median 9 months).
Before radiotherapy seven patients had apparent complete
macroscopic tumour removal, 62 partial removal and 46
biopsy alone (one uninown extent). Patients gave informed
consent to receive accelerated treatment. The tumour extent
was defined on contrast-enhanced preoperative CT and/or
MR images. All patients received planed radiotherapy to a
target volume defined as the region of enhancement on pre
operative CT and/or MRI scans plus a 3 cm margin. In
unenhancing tumours a 2-3 cm margin was added to the
region of abnormality. The dose to the target volume was
prescribed to 100% (normalised to the point of intersection
of beams). The maximum target volume inhomogeneity wasM Brada eti
Table I Patient characteistics and survival
Suviwal(%)
at
Characteristic Patients Deaths I year 2 years Signficance
All patients 116 92 33 13
Sex NS
Male 74 59 29 14
Female 42 33 41 17
Age (years) P<0.005
<55 53 39 46 29
55 63 53 22 3
KPS before radiotherapy P<0.01
< 70 17 16 6 0
>70 99 76 38 18
Grade NS
III 32 26 43 30
IV 44 39 26 8
Unspified 39
Surgery NS
None/biopsy 46 36 25 12
Partial 62 49 41 16
Complete 7 6 17 17
Fits NS
None 77 61 35 15
History<3 months 19 19 29 16
History 3 months 12 12 32 11
KPS, Karnofsky performance status; NS, not statistically significant.
10%. Patients were treated on a 5 or 6 MV linear accelerator
with two or three fields ofirradiation as defined on treatment
planing Radiotherapy was given twice a day with a
minimum 6h gap between fractions to a dose of 55Gy.
Sixteen patients received 32, 57 patients 34 and 38 patients 36
fractions (including 2 in 35 and 2 in 37 fractions), at 1.72,
1.62 or 1.53 Gy dose per fraction respectively. Five patients
did not complete radiotherapy: two died before completion
and three suffered progressive neurological deterioration and
treatment was discontinued. No adjuvant or neoadjuvant
therapy was given.
The cnical assessment of functional status was performed
using a Karnofsk-y performance index and WHO score, and
in the later part of the study patients were using a
modified baly i Barthel index (Laing et al.,
1993). The treatment at the time of relapse was individ-
ualised: 15 patients were treated with nitrosourea-containing
chemotherapy, ten patients received Temozolomide and three
patients were entered into the stereotactic radiotherapy prog-
ramme. A further two patients had stereotactic radiotherapy
after failing to respond to chemotherapy.
Survwal was caculated from the date of diagnosis by the
Kaplan-Meier method. The Cox's proportional hazards
model was used to define independent prognostic factors
(Cox, 1972).
Matched controls
Control patients were identified from the group of patients
allocated (but not necesarily completing) a 60 Gy schedule
within the MRC BR2 trial (MRC Brain Tumour Working
Party, 1990). This trial compared 45 Gy given in 20 fractions
over 4 weeks with 60 Gy in 30 fractions. In the latter
schedule the initial 40 Gy was given to a volume that encom-
passed all known and potential tumour followed by 20 Gy to
a reduced target volume to encompass the defined tumour
with a I cm margin.
Using prognostic factors identified from a previous MRC
trial (MRC Brain Tumour Working Party, 1990), an attempt
was made to match each accelerated radiotherapy patient
with a control from the MRC BR2 cohort. Thus controls
were of the same age ± 5 years (in practice most were of
identical age), with a similar history of fits (none, less than 3
months from diagnosis or more than 3 months from diag-
nosis), the same preradiotherapy WHO performance status
and the same extent ofprevious neurosurgery (biopsy, partial
resection, complete resection).
The end point used to compare patients and their matched
controls was survival time, dated from the start of
radiotherapy. Survival curves were calulated using the Kap-
lan-Meier method, and compared using the log-rank test
(Peto et al., 1977). The hazard ratio was used as an estimate
of the ratio of median survival times.
RCesM
A total of 116 patients with high-grade glioma were treated
with accelerated radiotherapy between 1988 and 1993. A
total of 111 patients completed the planned treatment. The
median survival of the whole cohort was 10 months with
33% suriving 1 year, 13% surviving 2 years and 5% surviv-
ing 3 years (Table I and Figure 1).
Age and preradiotherapy performance status were
significant independent prognostic factors for survival on
multivariate analysis (Table I). Gender, histological grade,
the extent of surgery and previous history of seizures were
not of prognostic signifi .
Time (months)
Fugwe 1 Actuaial surval of 116 patients with high-grade
glioma treated with accelerated radiotherapy.
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Following the start of accelerated radiotherapy, seven
patients had a transient deterioration in performance status
without tumour progression - six during treatment and one
11 weeks after the start. The duration ofdeterioration ranged
from 3 to 8 weeks and subsequent improvement was main-
taine for an average of 30 weeks. Three patients retuned to
their previous status and four did not fully recover
neurologically. Four patients required an interruption m
radiotherapy owing to the transient deterioration. Fifteen
further patients began to decline during radiotherapy owing
to presumed tumour progression and continued to
deteriorate without recovery. Four did not complete the
course of treatment. The remaining 83 patients improved or
remained stable throughout treatment.
Comparison with matched controls
Matched controls could be found only for 101 patients
treated with accelerated radiotherapy (Table I). Their mean
age was 52.6 years (s.d. 10) and for the matched controls 52.9
years (s.d. 10).
Three of the control patients remain alive with follow-up
of 407, 687 and 1577 days; 14 patients treated with
accelerated radiotherapy are alive with follow-up between 42
and 1180 days (median 354 days). Because of the difference
in length of follow-up, two analyses were performed. The
first included all 101 study patients and their matched cont-
rols. The survival comparison is shown in Table Im and
Figure 2. There is a suggestion of a slightly different survival
pattern, with the study patients having a higher death rate in
the first 12 months; however, the survival curves beyond this
point are similar, and the overall log-rank comparison gave a
P-value of 0.39. The hazard ratio was 1.13, with 95%
confidence limits 0.85-1.51. In the second analysis, only
those patients treated before the end of 1992 were included
(84 patients), together with their matched controls. The
results were very similar, with a hazard ratio of 1.12 (95% CI
0.8-1.53).
DiSaOw
Radiotherapy emnains the most effective treatment modality
in patients with high-grade glioma (Brada, 1989), although
Table n Characteristics of 101 patients treated with acrated
radiotherapy and matched with controls from MRC BR2 trial
Number of
Characteristic Group patients
WHO performance status
0-1 71
2 26
3-4 4
Extent ofsurgery
Biopsy 42
Partial removal 53
Complete removal 6
Fits
None 66
History <3 months 23
History >3 months 12
the results of treatment remain poor with median survival
less than I year. Little success has been achieved with
attempts to improve results using radiosensitisers, hyperbaric
oxygen, neutron beam therapy or altered fractionation.
Although radiotherapy is largely a palliative treatment aim-
ing to improve quality of life as well as prolonging survival,
the total dose required for optimum tumour control is in the
region of 60 Gy, equivalent to a radical course of
radiotherapy. A randomised study comparing 45 Gy in 20
fractions with 60 Gy in 30 fractions has shown a survival
advantage for patients treated with 60 Gy (Bleehen et al.,
1991), while in a randomised study the addition of a 10 Gy
boost following 60 Gy to the whole brain (to a total tumour
dose of70 Gy) did not prolong survival further (Chang et al.,
1983). Conventional radiotherapy given daily over 6 weeks
may therefore be considered optimal for large-volume frac-
tionated external beam radiotherapy, but in the light of the
poor overall survival the length of treatment may not be
acceptable to patients or their carers.
The duration of radiotherapy can be reduced by hypofrac-
tionation or accelerated fractionation. Hypofractionated
radiotherapy, giving an identical total dose of radiation at
larger doses per fraction, is considered to carry an unaccep-
table risk of late normal tissue damage. Tested in a conser-
vative form as 45 Gy in 20 fractions of 2.5 Gy per fraction,
the survival results also appear to be inferior to conventional
full dose irradiation (Bleehen et al., 1991). The question
Lemains whether full dose radiation can be given over a
shorter period of time using accelerated radiotherapy.
The traditional radiotherapy schedule of 60 Gy in 30 daily
fractions was modified to an accelerated schedule of 55 Gy in
34 fractions on the basis of radiobiological considerations.
The repair of radiation damage in the CNS may not be
completed in the 6 hour interval between fractions (Ang et
al., 1992). Clinical studies of continuous hyperfractionated
accelerated radiotherapy (CHART) in which the inter-
fraction interval was reduced to 4 hours resulted in an unex-
pectedly high incidence of myelopathy (Dische et al., 1988;
Dische, 1991) most likely because of incomplete repair
between fractions. Experimental evidence would suggest 16%
reduction in isoeffect dose for myelopathy when the inter-
100
Controls (MRC BR2 study)
80- Accelerated RT
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0'3 0 1 2 3
Time from start of RT (years)
F e 2 Survival comparison of 101 patients with high-grade
gaiom treated with acceerated radiotherapy and 101 matched
control patients treated with conventional daily radiotherapy in
an MRC BR2 trial. Survival was measured from the start of
radiation therapy.
Table m Suival comparison of patients treated with aclerated radiotherapy and matched
contuols receiving daiy fractionation
Number Number of
of deaths Hazard ratio Log-rank
Treatment patients Observed Expected (95%CI) X2 p
Accelerated 101 82 78
radiotherapy (study)
1.13 (0.85-1.51) 0.73 0.39
Conventional 101 91 95
radiotherapy (control)M*Brad -t - y Mr Brd et a
Table IV Radiotherapy studies ofhyperfracted and/or acceklrated radiotherapy
Study authors No.of Dose/fraction Treatments Totaldkose" Treatment Survival
Study design' patients (Gy) /day (Gy) time (weeks) advantage
Douglas etal. (1982) N 30 1.0 3 45-60 + lOB 5 Yes
Payne etal. (1982) R 157 1.0 4 36-40 2 No
Shin etal. (1983) R 69 0.89 3 40+ lOB 4 Yes
Fulton et al. (1984) R ? 0.89 3 61.4 4.5 No
Keim etal. (1987) N 47 1.6 3 60 2 No
Ludgate et al. (1988) R 76 0.76 3 40 vs 47.6 + lOB 5 No
Deutsch etal. (1989) R 603 1.1 3 66 6 No
Hernandez etal. (1990) N 14 1.0 3 55 3 No
Goffinan etal. (1992) N 45 1.5 2 70-75 5 No
Curran etal. (1992) R 304 1.6 2 48 vs 54.4 3.5 No
Nelson et al. (1993) R 435 1.2 2 64.8-72 vs 76.8 6 No
R 1.2 2 72vs81.6 6 No
'R, randomised; N, non-randomised. bB, boost.
fraction interval is reduced from 24 to 8 h (Ang et al., 1992).
The accelerated schedule was therefore modified to a total
dose of 55 Gy which was sequentially given in 36, 34 and 32
fractions.
The overall results of this approach with a median survival
of 10 months are similar to those of other large series. There
was also no significant difference in survival between
accelerated radiotherapy patients and controls matched for
major prognostic factors who had 60 Gy in 30 daily fractions
in a previous MRC study. While the results suggest equiva-
lent efficacy in terms of survival, this is not a randomised
study, and it is possible that patients receiving accelerated
radiotherapy and the control group are unbalanced with
respect to some unknown prognostic factor. The P-value
(Table III) cannot therefore have the same meaning as a
randomised comparison. Assuming exponential survival times
with the hazard ratio used as an estimate of the ratio of
median survival times (Table III), the value of 1.13 corres-
ponds to an estimated increase in median survival time in
control patients of approximately 5 weeks. However, the
95% confidence limits do not exclude a 7 week lengthening
of median survival.
If repopulation during a protracted course of radiotherapy
is an important factor determining relapse of high-grade
glioma, then accelerated radiotherapy might be expected to
improve survival. Failure to demonstrate an improvement
does not exclude the possibility that repopulation contributes
to poor results following radiation, but suggests that it is less
important than other parameters determining outcome.
It is feared that accelerated radiotherapy could increase
acute morbidity as well as reduce survival by increasing
mortality due to early and late CNS damage. While there
was no evidence of increased mortality, acute CNS toxicity is
difficult to measure. During treatment six patients had a
transient deterioration in performance status and one patient
had a transient (3 week) deterioration after 11 weeks. Such
transient effects could have been either treatment related with
subsequent recovery or due to tumour progression with
delayed response to treatment. There is no information on
the incidence of similar events in patients treated conven-
tionally. In our experience this type of morbidity is similar,
although an increased risk of early neurological impairment
cannot be excluded on the basis of these data. Accelerated
hyperfractionated radiotherapy to a dose of 54.4 Gy was
compared with 48 Gy (both at 1.6 Gy per fraction twice
daily) in a RTOG study 83-02 with similar early toxicity and
survival results (Curran et al., 1992).
Fifteen patients had a gradual continuous decline in per-
formance status which began during radiotherapy. It is
difficult to separate any possible treatment-related deteriora-
tion from progressive unresponsive disease. Theoretically,
deterioration due to incomplete repair and subsequent nec-
rosis of normal tissue would not be manifest until weeks or
months after the end of treatment.
Other groups have used altered fractionation in an attempt
to improve survival results (Table IV). Only two small studies
ofhyperfractionation have shown a possible benefit (Douglas
and Worth 1982; Shin et al., 1983). The majority of studies
did not demonstrate prolongation of survival (Table IV) and
overall have little advantage compared with conventional
fractionation. Increasing the total dose using hyperfractiona-
tion has also been tested. Patients treated in a RTOG trial
83-02 testing hyperfractionated accelerated radiotherapy to
54.4 Gy had a median survival of 10.8 months with little
early toxicity (Curran et al., 1992). In a randomised dose-
searching phase I/II study of the RTOG (Nelson et al., 1993),
patients received doses of 1.2 Gy per fraction twice daily.
The total doses ranged from 64.8 Gy to 81.6 Gy (four dose
levels) and treatment was given over a period of 5.5-6.5
weeks together with adjuvant BCNU. There was no survival
benefit with higher radiation doses and even a suggestion of
worse results with doses > 74.5 Gy. Overall accelerated and/
or hyperfractionated radiotherapy is therefore of little addi-
tional survival benefit.
We conclude that in patients with high-grade glioma
radiotherapy treatment time can be reduced from 6 to just
over 3 weeks without a marked increase in toxicity or loss of
survival benefit. The short overall survival in these patients
precludes any definite conclusion about the long-term safety
of high-dose accelerated irradiation. There are logistic prob-
lems in this approach which require reorganisation of treat-
ment machine time and occasionally provision of day care or
in-patient facilities for patients unable to attend twice daily.
This and the overall higher number of fractions have clear
financial implications for the service. Nevertheless, in our
experience accelerated radiotherapy is feasible and acceptable
to patients, staff and carers and has become an available
treatment for selected patients who wish to complete therapy
in a shorter time.
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